v3.26.3
Basis of Presentation and Material Accounting Policies
3 Months Ended
Jul. 31, 2026
Basis Of Accounting [Abstract]  
BASIS OF PRESENTATION AND MATERIAL ACCOUNTING POLICIES
2.
BASIS OF PRESENTATION AND MATERIAL ACCOUNTING POLICIES
(a)
Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). They are condensed as they do not include all of the information required for full annual financial statements, and they should be read in conjunction with the audited annual consolidated financial statements ("annual consolidated financial statements") of the Company for the year ended April 30, 2026 which are available on SEDAR at www.sedarplus.ca and with the SEC at www.sec.gov.

Certain items have been reclassified in the prior year financial statements to conform to the presentation and classification used in the current year and for discontinued operations. These reclassifications had no effect on the Company's consolidated operating results, financial position or cash flows.

These condensed interim consolidated financial statements were approved by the Company's Board of Directors on September 14, 2026.

(b)
Basis of measurement

These condensed interim consolidated financial statements have been prepared on the historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information.

(c)
Basis of consolidation

These condensed interim consolidated financial statements include the financial statements of the Company and the following subsidiaries, using their historical names, which are wholly owned and subject to control by the Company:

 

 

Name of Subsidiary

 

% Equity
Interest -
July 31, 2026 and
April 30, 2026

 

Country of
Incorporation

 

Functional Currency

ImmunoPrecise Antibodies (Canada) Ltd. d/ba/ MindWalk Biologics

 

100%

 

Canada

 

Canadian dollar

ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Antibodies (N.D.) LTD

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Antibodies (MA) LLC

 

100%

 

USA

 

U.S. dollar

Talem Therapeutics LLC ("Talem")

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Netherlands B.V.

 

100%

 

Netherlands

 

Euro

BioStrand B.V. d/b/a MindWalk

 

100%

 

Belgium

 

Euro

Idea Family BV

 

100%

 

Belgium

 

Euro

BioKey BV

 

100%

 

Belgium

 

Euro

BioClue BV

 

100%

 

Belgium

 

Euro

 

Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with an entity and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation.

(d)
Functional and presentation currency

The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements. The presentation currency of the Company is the Canadian dollar.

Foreign currency translation

Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences.

Foreign currency transactions

Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss.

When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

(e)
Discontinued Operations

 

The following table summarizes the major classes of line items included in income from discontinued operations, net of tax, as a result of the divestiture of IPA Europe and reclassification to discontinued operations:

 

 

 

Three months ended July 31,

 

(in thousands, except share data)

 

2026
$

 

 

2025
$

 

REVENUE

 

 

—

 

 

 

4,480

 

COST OF SALES

 

 

—

 

 

 

1,976

 

GROSS PROFIT

 

 

—

 

 

 

2,504

 

EXPENSES

 

 

 

 

 

 

Research and development

 

 

—

 

 

 

115

 

Sales and marketing

 

 

—

 

 

 

117

 

General and administrative

 

 

—

 

 

 

778

 

Amortization of intangible assets

 

 

—

 

 

 

109

 

 

 

 

—

 

 

 

1,119

 

Income before other income (expenses) and income taxes

 

 

—

 

 

 

1,385

 

OTHER INCOME (EXPENSES)

 

 

 

 

 

 

Grant income

 

 

—

 

 

 

6

 

Interest, accretion and other income

 

 

—

 

 

 

—

 

Unrealized foreign exchange loss

 

 

—

 

 

 

(1

)

 

 

 

—

 

 

 

5

 

Income before income taxes

 

 

—

 

 

 

1,390

 

Income taxes

 

 

—

 

 

 

(261

)

NET INCOME FROM DISCONTINUED OPERATIONS

 

 

—

 

 

 

1,129